EGFR and non-small cell lung carcinoma: Depletion of MSI2 in NSCLC cells significantly decreased cell invasion and metastasis via TGF-β signaling [17], and potentiated chemotherapy response to EGFR inhibitors in EGFR-mutated NSCLC cells [18].